Literature DB >> 2334155

Inhibition of norfloxacin absorption by antacids.

D E Nix1, J H Wilton, B Ronald, L Distlerath, V C Williams, A Norman.   

Abstract

The effect of antacids on the systemic absorption of oral norfloxacin was evaluated in 12 healthy volunteers. Subjects were given each treatment in a balanced sequence at 7-day intervals. Treatments included 400 mg of norfloxacin alone, 400 mg of norfloxacin 5 min after aluminum-magnesium hydroxide (Maalox), Maalox 2 h after 400 mg of norfloxacin, and 400 mg of norfloxacin 5 min after calcium carbonate (Titralac). Blood and urine samples were collected at predetermined time intervals for 24 and 48 h, respectively. Norfloxacin concentrations in plasma and urine were determined by high-pressure liquid chromatography. The area under the plasma concentration-versus-time curve from time zero to infinity and urinary recovery were used to compare the relative bioavailability of norfloxacin with antacids with that of norfloxacin alone. Norfloxacin bioavailability was markedly reduced when subjects received antacid pretreatment. When norfloxacin was given 5 min after Maalox and Titralac, the bioavailabilities were 9.02 and 37.5%, respectively, relative to that for 400 mg of norfloxacin alone. When Maalox was given 2 h after norfloxacin, maximal concentrations of norfloxacin in plasma occurred between 1 and 1.5 h postdose, and absorption was reduced to a lesser extent, with a relative bioavailability of 81.31%. Norfloxacin concentrations in urine were also reduced as a result of antacid administration. Antacids containing aluminum and magnesium salts and calcium carbonate should be avoided by patients taking norfloxacin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2334155      PMCID: PMC171610          DOI: 10.1128/AAC.34.3.432

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  THE LOCALIZATION AND TREATMENT OF URINARY TRACT INFECTIONS: THE ROLE OF BACTERICIDAL URINE LEVELS AS OPPOSED TO SERUM LEVELS.

Authors:  T A STAMEY; D E GOVAN; J M PALMER
Journal:  Medicine (Baltimore)       Date:  1965-01       Impact factor: 1.889

2.  Reduced enteral absorption of ciprofloxacin in the presence of antacids.

Authors:  G Höffken; K Borner; P D Glatzel; P Koeppe; H Lode
Journal:  Eur J Clin Microbiol       Date:  1985-06       Impact factor: 3.267

3.  Influence of pH and human urine on the antibacterial activity of ciprofloxacin, norfloxacin and ofloxacin.

Authors:  H J Zeiler
Journal:  Drugs Exp Clin Res       Date:  1985

4.  Ciprofloxacin and antacids.

Authors:  L C Preheim; T A Cuevas; J S Roccaforte; M A Mellencamp; M J Bittner
Journal:  Lancet       Date:  1986-07-05       Impact factor: 79.321

5.  Unexpected mobilisation of lead during cisplatin chemotherapy.

Authors:  A M el-Sharkawi; W D Morgan; S Cobbold; M B Jaib; C J Evans; L J Somervaille; D R Chettle; M C Scott
Journal:  Lancet       Date:  1986-08-02       Impact factor: 79.321

6.  Interactions of aluminum, magnesium, and calcium ions with nalidixic acid.

Authors:  M Nakano; M Yamamoto; T Arita
Journal:  Chem Pharm Bull (Tokyo)       Date:  1978-05       Impact factor: 1.645

Review 7.  Ciprofloxacin and norfloxacin, two fluoroquinolone antimicrobials.

Authors:  D E Nix; J M DeVito
Journal:  Clin Pharm       Date:  1987-02

8.  Effects of changes in pH, medium and inoculum size on the in vitro activity of different quinolone and fluoroquinolone antibiotics against urinary pathogens.

Authors:  G P Gesu; C Eftimiadi; E Debbia; G C Schito
Journal:  Drugs Exp Clin Res       Date:  1987

9.  Norfloxacin disposition after sequentially increasing oral doses.

Authors:  B N Swanson; V K Boppana; P H Vlasses; H H Rotmensch; R K Ferguson
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

  9 in total
  25 in total

1.  Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers.

Authors:  H Stass; M F Böttcher; K Ochmann
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  The effect of four different types of food on the bioavailability of cefaclor.

Authors:  S Karim; T Ahmed; T Monif; N Saha; P L Sharma
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Jul-Sep       Impact factor: 2.441

3.  Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans.

Authors:  K Shiba; O Sakai; J Shimada; O Okazaki; H Aoki; H Hakusui
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

4.  Inhibition of norfloxacin absorption by dairy products.

Authors:  K T Kivistö; P Ojala-Karlsson; P J Neuvonen
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

5.  Effects of two cations on gastrointestinal absorption of ofloxacin.

Authors:  M Martínez Cabarga; A Sánchez Navarro; C I Colino Gandarillas; A Domínguez-Gil
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

6.  Pharmacokinetics of single-dose intravenous, oral, and intraperitoneal pefloxacin in patients on chronic ambulatory peritoneal dialysis.

Authors:  J L Schmit; L Hary; P Bou; H Renaud; P F Westeel; M Andrejak; A Fournier
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

Review 7.  Fluoroquinolones: interaction profile during enteral absorption.

Authors:  K M Deppermann; H Lode
Journal:  Drugs       Date:  1993       Impact factor: 9.546

8.  Effect of oral antacids on disposition of intravenous enoxacin.

Authors:  D E Nix; M E Lebsack; M Chapelsky; A J Sedman; J Busch; A Norman
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

Review 9.  Drug interactions with quinolone antibacterials.

Authors:  J R Brouwers
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

Review 10.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.